Effect of a high dose of glucosamine on systemic and tissue inflammation in an experimental model of atherosclerosis aggravated by chronic arthritis.

Glucosamine sulfate (GS) is a glycosaminoglycan with anti-inflammatory and immunoregulatory properties. Here we set out to explore the effect of GS administration on markers of systemic and local inflammation in rabbits with atherosclerosis aggravated by chronic arthritis. Atherosclerosis was induced in rabbits by maintaining them on a hyperlipidemic diet after producing an endothelial lesion in the femoral arteries. Simultaneously, chronic arthritis was induced in these animals by repeated intra-articular injections of ovalbumin in previously immunized rabbits. A group of these rabbits was treated prophylactically with oral GS (500 mg.kg(-1).day(-1)), and, when the animals were killed, serum was extracted and peripheral blood mononuclear cells (PBMC) were isolated. Furthermore, the femoral arteries, thoracic aorta, and synovial membranes were examined in gene expression studies and histologically. GS administration reduced circulating levels of the C-reactive protein and of interleukin-6. GS also lowered nuclear factor-kappaB activation in PBMC, and it downregulated the expression of both the CCL2 (monocyte chemoattractant protein) and cyclooxygenase-2 genes in these cells. Lesions at the femoral wall were milder after GS treatment, as reflected by the intimal-to-media thickened ratio and the absence of aortic lesions. Indeed, GS also attenuated the histological lesions in synovial tissue. In a combined rabbit model of chronic arthritis and atherosclerosis, orally administered GS reduced the markers of inflammation in peripheral blood, as well as the femoral and synovial membrane lesions. GS also prevented the development of inflammation-associated aortic lesions. These results suggest an atheroprotective effect of GS.

[1]  R. Marchase,et al.  Glucosamine improves cardiac function following trauma-hemorrhage by increased protein O-GlcNAcylation and attenuation of NF-{kappa}B signaling. , 2009, American journal of physiology. Heart and circulatory physiology.

[2]  G. Herrero-Beaumont,et al.  Chronic arthritis aggravates vascular lesions in rabbits with atherosclerosis: a novel model of atherosclerosis associated with chronic inflammation. , 2008, Arthritis and rheumatism.

[3]  G. Herrero-Beaumont,et al.  Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis , 2008, British journal of pharmacology.

[4]  S. Oparil,et al.  Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury. , 2008, American journal of physiology. Heart and circulatory physiology.

[5]  S. Momohara,et al.  Serum amyloid A activates nuclear factor-kappaB in rheumatoid synovial fibroblasts through binding to receptor of advanced glycation end-products. , 2008, The Journal of rheumatology.

[6]  Y. Devaux,et al.  C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor α, on human monocytes , 2008, Thrombosis and Haemostasis.

[7]  C. Meisinger,et al.  Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984-1998. , 2008, Clinical chemistry.

[8]  B. Foxwell,et al.  Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. , 2008, Rheumatology.

[9]  Jianjun Li,et al.  Decreased infiltration of macrophages and inhibited activation of nuclear factor-kappa B in blood vessels: a possible mechanism for the anti-atherogenic effects of losartan , 2007, Acta cardiologica.

[10]  D. Scott‐Algara,et al.  Antiinflammatory and Antiatherogenic Effects of the NF-&kgr;B Inhibitor Acetyl-11-Keto-β-Boswellic Acid in LPS-Challenged ApoE−/− Mice , 2007 .

[11]  B. Goswami,et al.  Atherosclerosis Pathophysiology and the Role of Novel Risk Factors: A Clinicobiochemical Perspective , 2007, Angiology.

[12]  B. Jang,et al.  Glucosamine Hydrochloride Specifically Inhibits COX-2 by Preventing COX-2 N-Glycosylation and by Increasing COX-2 Protein Turnover in a Proteasome-dependent Manner* , 2007, Journal of Biological Chemistry.

[13]  J. Pelletier,et al.  Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues , 2007, Annals of the rheumatic diseases.

[14]  M. Grynpas,et al.  The effects of glucosamine hydrochloride on subchondral bone changes in an animal model of osteoarthritis. , 2007, Arthritis and rheumatism.

[15]  W. Ollier,et al.  HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[16]  G. Herrero-Beaumont,et al.  The reverse glucosamine sulfate pathway: application in knee osteoarthritis , 2007, Expert opinion on pharmacotherapy.

[17]  J. Egido,et al.  Licofelone, a Balanced Inhibitor of Cyclooxygenase and 5-Lipoxygenase, Reduces Inflammation in a Rabbit Model of Atherosclerosis , 2007, Journal of Pharmacology and Experimental Therapeutics.

[18]  R. Morishita,et al.  Stent-Based Local Delivery of Nuclear Factor-&kgr;B Decoy Attenuates In-Stent Restenosis in Hypercholesterolemic Rabbits , 2006, Circulation.

[19]  M. Popp,et al.  Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1β , 2006, Arthritis research & therapy.

[20]  P. Rossignol,et al.  Plasminogen activator inhibitor-1 impairs plasminogen activationmediated vascular smooth muscle cell apoptosis , 2006, Thrombosis and Haemostasis.

[21]  K. Yudoh,et al.  Effects of glucosamine administration on patients with rheumatoid arthritis , 2006, Rheumatology International.

[22]  Purificación Hernández-Vargas,et al.  Parthenolide Modulates the NF-&kgr;B–Mediated Inflammatory Responses in Experimental Atherosclerosis , 2006 .

[23]  G. Herrero-Beaumont,et al.  Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac , 2006, Annals of the rheumatic diseases.

[24]  G. Hansson,et al.  Inflammation and atherosclerosis. , 2006, Annual review of pathology.

[25]  Wen-zhuo Duan,et al.  Distinct effects of glucose and glucosamine on vascular endothelial and smooth muscle cells: Evidence for a protective role for glucosamine in atherosclerosis , 2005, Cardiovascular diabetology.

[26]  M. González-Gay,et al.  High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.

[27]  J. Hua,et al.  Preventive actions of a high dose of glucosamine on adjuvant arthritis in rats , 2005, Inflammation Research.

[28]  C. Monaco,et al.  Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. , 2004, Cardiovascular research.

[29]  I. McInnes,et al.  Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. , 2003, Circulation.

[30]  E. Yeh,et al.  Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells , 2003, Circulation.

[31]  G. Herrero-Beaumont,et al.  Glucosamine inhibits IL-1β-induced NFκB activation in human osteoarthritic chondrocytes , 2003 .

[32]  K. Hatakeyama,et al.  Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. , 2003, The American journal of cardiology.

[33]  D. Praticò,et al.  Effect of Low-Dose Aspirin on Vascular Inflammation, Plaque Stability, and Atherogenesis in Low-Density Lipoprotein Receptor–Deficient Mice , 2002, Circulation.

[34]  M. Uldry,et al.  GLUT2 is a high affinity glucosamine transporter , 2002, FEBS letters.

[35]  R. Quirion,et al.  The role of spinal neuropeptides and prostaglandins in opioid physical dependence , 2002, British journal of pharmacology.

[36]  Shing‐Jong Lin,et al.  Magnolol attenuates VCAM‐1 expression in vitro in TNF‐α‐treated human aortic endothelial cells and in vivo in the aorta of cholesterol‐fed rabbits , 2002 .

[37]  G. Wu,et al.  Glucosamine inhibits inducible nitric oxide synthesis. , 2000, Biochemical and biophysical research communications.

[38]  M. Wasko,et al.  Inflammation-mediated rheumatic diseases and atherosclerosis , 2000 .

[39]  F. Ronca,et al.  Anti-inflammatory activity of chondroitin sulfate. , 1998, Osteoarthritis and cartilage.

[40]  I. Adcock,et al.  Evidence for Involvement of NF-κB in the Transcriptional Control of COX-2 Gene Expression by IL-1β ☆ , 1997 .

[41]  M. Karin,et al.  Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. , 1997, The New England journal of medicine.

[42]  J. Egido,et al.  Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. , 1997, Circulation.

[43]  M. McCarty.  Glucosamine may retard atherogenesis by promoting endothelial production of heparan sulfate proteoglycans. , 1997, Medical hypotheses.

[44]  F. Wolfe,et al.  The mortality of rheumatoid arthritis. , 1994, Arthritis and rheumatism.

[45]  J. Egido,et al.  NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability. , 2004, Stroke.

[46]  I Petersen,et al.  Grading of chronic synovitis--a histopathological grading system for molecular and diagnostic pathology. , 2002, Pathology, research and practice.

[47]  A. Chait,et al.  Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. , 2002, Journal of lipid research.

[48]  P. Tak,et al.  NF-κB: a key role in inflammatory diseases , 2001 .

[49]  M. Laakso,et al.  Cardiovascular mortality in patients with rheumatoid arthritis. , 1989, Cardiology.

[50]  Lipids, Lipoproteins, and Cardiovascular Risk Factors Tissue Factor and Monocyte Chemoattractant Protein-1 Expression in Hypertensive Individuals with Normal or Increased Carotid Intima-Media Wall , 2022 .